市场调查报告书
商品编码
1382482
睡眠药物市场规模 - 按类型(处方药、非处方药)、药物类别(苯二氮平类药物、抗忧郁药、抗组织胺)、睡眠障碍类型、2023-2032 年全球预测Sleep Medications Market Size - By Type (Prescription-based, OTC), Drug Class (Benzodiazepines, Antidepressants, Antihistamines), Sleep Disorder Type, Global Forecast 2023-2032 |
预计从 2023 年到 2032 年,睡眠药物市场规模将以超过 6.8% 的CAGR增长。不断上升的压力水平和忙碌的生活方式导致全球睡眠障碍患病率激增。老年人口的不断增长、慢性病发病率的增加以及人们对睡眠习惯重要性的认识不断提高,都推动了产品需求。
此外,久坐的生活方式和精神健康疾病的高盛行率进一步加速了有效睡眠药物的采用,促进了市场扩张。哈佛医学院和昆士兰大学研究人员共同领导的一项大规模研究表明,全球 50% 的人口到 75 岁时将患上至少一种精神健康疾病。随着心理健康问题的发展,未来几年对睡眠药物的需求也会增加。
整个睡眠药物市场根据类型、药物类别、睡眠障碍类型和地区进行分类。
预计 2023 年至 2032 年,非处方药领域的CAGR将达到 7.1%,这主要是由于易于取得以及消费者对自我药疗的日益偏好。随着几种可快速缓解常见睡眠障碍的非处方药睡眠辅助剂的推出,消费者越来越倾向于使用这些药物。在领先製药公司采用的产品创新和行销策略的支持下,对非处方安眠药的需求持续成长。
预计 2023 年至 2032 年,不宁腿睡眠障碍 (RLSD) 领域的CAGR将达到近8.4%。普通人群对这种疾病的认识不断提高,导致对针对这种特殊病症的特定药物的需求增加。市场参与者积极参与研发活动,以推出有效的配方。确诊病例数量的增加以及专注于解决其症状的新型治疗方案的开发将有助于该细分市场的成长。
由于中国、印度和日本等国家的快速城市化、生活方式的改变以及睡眠障碍盛行率的增加,2023年至2032年亚太地区睡眠药物市场的CAGR将达到7.9%左右。该地区的医疗基础设施正在不断改善,加上人们对睡眠健康重要性的认识不断提高,预计将推动市场成长。这些製药公司策略性地致力于透过推出客製化产品和加强分销网络来扩大其在亚太市场的影响力,从而充分利用该地区不断增长的机会。
Sleep medications market size is predicted to grow at over 6.8% CAGR from 2023 to 2032. The rising stress levels and hectic lifestyles have led to an upsurge in the prevalence of sleep disorders globally. The growing elderly population, increasing incidences of chronic diseases, along with the improved awareness about the importance of sleep routine are fueling the product demand.
Moreover, the adoption of sedentary lifestyles and the high prevalence of mental health disorders have further accelerated the adoption of effective sleep medications, fostering market expansion. According to a large-scale study co-led by researchers at Harvard Medical School and University of Queensland, 50% of the global population will develop at least one mental health disorder by the age of 75 years. As mental health issues develop, the need for sleep medications will also increase in the coming years.
The overall sleep medications market is classified based on type, drug class, sleep disorder type, and region.
The OTC drug segment is expected to observe 7.1% CAGR from 2023 to 2032, primarily due to the ease of accessibility and the growing preference for self-medication among the consumers. With the introduction of several OTC sleep aids that offer quick relief from common sleep disorders, consumers are increasingly inclined towards these medications. The demand for OTC sleep drugs continue to boost, supported by the product innovations and marketing strategies adopted by leading pharmaceutical companies.
The restless legs sleep disorder (RLSD) segment is anticipated to witness nearly 8.4% CAGR during 2023 and 2032. The rising awareness about the ailment among the common population is leading to an increased demand for specific medications catering to this particular condition. The market players are actively engaged in R&D activities to introduce effective formulations. The increasing number of diagnosed cases and the development of novel treatment options focusing on addressing its symptoms will aid the segment growth.
Asia Pacific sleep medication market will observe around 7.9% CAGR from 2023 to 2032 owing to the rapid urbanization, changing lifestyle patterns, and the increasing prevalence of sleep disorders in countries such as China, India, and Japan. The region is witnessing improvement in healthcare infrastructure, which along with the rising awareness about the importance of sleep health is expected to drive the market growth. The pharma companies are strategically focusing on expanding their presence in the Asia Pacific market by launching tailored products and strengthening distribution networks, thereby capitalizing on the growing opportunities in this region.